The Poster Corridor

You can put a poster about your work or technology which is related to the session topics of the FABS. Number of place is limited.

If you want to propose a poster, please note that:

• the poster is of your charge
• you have to bring it with you the day of the seminar. We will fix it with "double face gum", no handling.
• the poster has to be a maximum size of 1 meter long and 80 centimeter large
• you have to fill the template poster that will be distributed during the seminar to all of the participants.

To fill the poster template, please download the file

Deadline submission for the poster template : March, 23^th 2009, by answering back to my email jointly with the completed template poster : isabelle.scarabin@lyonbiopole.com

Come and participate to the FABS, a new format of symposium that aims to

==>  Promote cooperation in science and technologie between France and United States
==>  Promote collaborative initiatives in research and innovation between France and 

        United States in the field  of Infectious Diseases

==>  Participate in the debate between Industry, Biotech Companies and Research   

        Laboratories
==>  Present needs and skills to firms and public research laboratories
==>  Develop new opportunities for partnerships and R&D projects between France and

        United States

                                       Download the program (PDF) 

Day 1 Monday, March 30

8.30 am Registration

9.00 am Welcome Talks
Alain Mérieux, President, Mérieux Foundation

Frederic Maerkle, Counselor for Environment, Science, Technology, Health and Nonproliferation Regimes of the United States in France

9.30 am  Session 1 - Vaccines:  Development and Goals, Epizooties Case Studies

Chairman:  Jeffrey Almond, Ph.D., Vice President, Discovery Research and External R&D, sanofi pasteur

Keynote Speaker:  Jacques Banchereau, Ph.D., Director, Baylor Institute for Immunology Research, Director, INSERM-U899, BIIR/ANRS/INSERM Center for Human Vaccines Professor, Department of Gene & Cell Medicine, Department of Medicine (Clinical Immunology Division) - MSSM,

Title:  Developing novel human vaccines by harnessing dendritic cells

Michael Franti, Ph.D., Molecular Virologist , Novartis Vaccines,

Title:  HIV antigen discovery and novel vaccine deliveries using recombinant alphavirus replicon particles

Jean François Nicolas, M.D., Ph.D., Clinical Immunology & Allergy Department, University Lyon 1, Hôpitaux de Lyon, Inserm U851, Lyon, France,

Title:  Skin vaccination: from immunology to clinical practice

Nicolas Mouz, Ph.D., Chief Scientific Officer and co-Founder, PX Therapeutics,

Title:  Gp41-based vaccine candidate can trigger mucosal antibodies that protects female macaques from intra-vaginal low dose challenges with SHIV,

Michel Goldman, Director, The Institute for Medical Immunology, Université Libre de Bruxelles ; Vice-President , BioWin, The Health Cluster of Wallonia,

Title:  Future vaccines in need of novel adjuvants:  how to address the challenge?

Farshad Guirakhoo, Ph.D., Senior Director, External R&D, US/France, Global Discovery and External R&D,  sanofi pasteur,

Title:  ChimeriVax^TM Technology: Applications for dengue, Japanese Encephalitic virus, West Nile Vaccines,

Luc Teyton, M.D., Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute,

Title:  Adjuvanticity of NKT cells and their usage for the development of better vaccine,

Michel Bublot, DVM, Ph.D., Merial, Title:  Veterinary Vectored Vaccines for Influenza,
Phil Felgner, Professor, University of California at Irvine,

Title:  Genome-wide Protein Microarrays for Vaccine and Serodiagnostic Antigen Discovery

Alain Rolland, Pharm.D., Ph.D., Executive Vice President, Product Development, Vical Inc., Title :  Vaxfectin® as an Adjuvant for DNA- and Protein-based Vaccines

Philippe Roingeard, Pharm.D., Ph.D., Head of INSERM U 966, INSERM & François Rabelais University, Tours, France,

Title: Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.

11.30 am Session 2 - Preclinical & Clinical Models:  Approaches and Strategies

Chairman:  Donald E. Mosier, Ph.D., M.D., Professor, Department of Immunology & Microbial Science, IMM-7, The Scripps Research Institute

Erwan Corcuff, CEO, Axenis, Project Leader, Pasteur Institute,

Title:  humanized animal models for preclinical evaluation of vaccine candidates,

Christopher J. Miller, DVM, PhD, Professor, California National Primate Research Center, University of California, Davis,

Title:  Judging preclinical effectiveness of antiviral vaccines and immunotherapies in nonhuman primate models

Philippe J. Goix, Ph.D., President and Chief Executive Officer, Singulex,

Title :  Utilizing novel immunoassay technology for pre-clinical and clinical data acquisition

Charlotte Dalba, M.D., Ph.D., CEO Epixis, Title:  RetroVLP- based vaccines: technology and application for Hepatitis C.

David Klatzmann, Professor, Director of the laboratory "Immunology-Immunopathology-Immunotherapy", UMR7211 UPMC/CNRS U959 INSERM, Pitié Salpétrière Hospital,

Title:  COMPUVAC: a European consortium for the rational development of novel vaccines

Emmanuel Chereul, Ph. D., General Manager, Voxcan, Hugues Contamin, Ph.D., DVM, CEO, Cynbiose,

Title:  Live imaging in non-human primates to revisit the pathogenesis and preclinical exploration of infectious diseases - The synergism between two new companies Cynbiose and Voxcan

01.00 pm: Lunch - Posters Sessions

2.00 pm: Workshops
Objective : To work together on scientific and technological themes to bring out new opportunities for partnerships and R&D projects between French and American
By group of 10 to 12 persons, themes are to be defined for registration

4.30 pm: Coffee break - Posters session

5.00 pm: Conclusions of the workshops in a plenary session and proposal of follow-up

6.00 pm: Networking Reception
Social event

* : to be confirmed

Chairman:  Dr Albert Osterhaus*, Head Department of Virology, Erasmus MC, Rotterdam, The Netherlands,

Gláucia Paranhos-Baccalà, PhD, Research Director of the Emerging Pathogens Laboratory, Fondation Mérieux,

Title:  Identification and Typing of Multi-pathogens of Acute Respiratory Lower Infections in Multi-sites in Developing and Emerging countries

Heather Koshinsky, Ph.D., CSO & Co Founder, Eureka Genomics,
Title:  Utilizing Next Generation Sequencing and Bioinformatics for the Discovery of Unknown Pathogens

Philippe Vanhems, M.D., Ph.D., Head of Department of Epidemiology and Infection Control, Hôpital Edouard Herriot, and Claude Bernard University Lyon,

Title:  Surveillance of hospital acquired infections : a tool for detecting emerging pathogens,

Laurent Coudeville, Ph.D., Health Economics Deputy Director, sanofi pasteur,
Title:  Dengue Epidemiology. Insights from a four-serotype transmission model,

Guénaël Rodier, M.D., Director, International Health Regulations Coordination Department, WHO Geneva,
Title:  International Health Regulations as the New Global Framework for Epidemic Control

11.00 am Coffee break - Posters session

11.30 am Session 4 - New Therapies : New Perspectives for Treatments

Chairman:  Christian Bréchot, VP, Medical & Scientific Affairs, Mérieux Alliance

Keynote Speaker:  Professor Dominique Charron, MD, PhD, UMRS INSERM 940, Hôpital Saint-Louis, Paris, France,

Titre : Vaccines and Autologous WBC infusion: Integration and Anticipation
 

Keynote Speaker:  Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Stufy of Drug Development, Editor - in - Chief, mAbs,

Title:  Global trends in the development of new anti-infective treatments

Camille Locht, Ph.D., Director, Inserm U 629 Molecular mechanisms of bacterial pathogenesis, Scientific Director, Institut Pasteur de Lille,

Title:  Rethinking latency to develop new tuberculosis vaccines and diagnostics,

Manohar John, Ph.D., Director, Department of Molecular Genetics, Oragenics,

Title:  Novel Platform Technologies for Rapid and Sensitive Biomarker Discovery

Ken Stuart, Professor, President and Director, Seattle Biomedical Research Institute,

Title:  Developing therapeutics for complex pathogens,

Guido Vanham, M.D., Ph.D., Head Virology Unit, Institute of Tropical Medicine,

Title:  Microbicides as a preventive tool against HIV infection

Karine Le Roch, Ph.D, Assistant Professor, Department of Cell Biology & Neuroscience, University of California Riverside,

Title:  Binary Alterations of Chromatin Structure Control a Rigid transcriptional device in the Human Malaria Parasite

Jean Yves Bonnefoy, Ph.D., VP, R&D, Transgene,

Title:  Targeted Immunotherapy and Biomarkers,

Jacques Descotes, MD, Pharm.D, Ph.D, Professor, Claude Bernard University and Head, Lyon Poison Center,

Title:  Non-clinical Safety Evaluation of Nanomedicines

Ludovic Tailleux, Ph.D., Mycobacterial Genetics Unit, Institut Pasteur,

Title:  Biomarkers of tuberculosis infection

01.00 pm Lunch - Posters Sessions

2.30 pm Business Meetings or Visits of Laboratories
- Face to Face will be planned, based on company and laboratories profiles exchanged between American and French participants
- A program of visits will be proposed in Lyon and Grenoble

5.30 pm Conclusions

6.00 pm Cocktail

* : to be confirmed

For more information:

Isabelle Scarabin
Development & International Director
Isabelle.scarabin@lyonbiopole.com
LYONBIOPOLE
Bâtiment Domilyon, 321 avenue Jean Jaurès,
F-69007 Lyon
Mob.: + 33 (0)6 32 57 92 87        
Tel. : + 33 (0)4 72 76 53 39        
Fax. :+ 33 (0)4 72 70 48 29
http://www.lyonbiopole.com/

Mireille Guyader, PhD
Attache for Science and Technology
attache-sdv.mst@consulfrance-losangeles.org
mireille.guyader@diplomatie.gouv.fr

Consulate General of France
10390 Santa Monica Boulevard, Suite 410
Los Angeles, CA, 90025
Tel : 310 235 3248        
Fax : 10 312 0704
Cell :424 653 8422
http://www.france-science.org/

Organized by The Office for Science and Technology at the French Consulate in Los Angeles and Lyonbiopole (Rhône-Alpes),
With the participation of the French BIO Clusters,
With the support of the French Ministry of Industry (DGCIS), the Rhone-Alpes Council, the Greater Lyon and Aderly.